See the DrugPatentWatch profile for Lupron
When does Lupron Depot (leuprolide) lose exclusivity in Canada?
“Lupron Depot” is marketed in Canada as a brand of long-acting leuprolide. The exact “loss of exclusivity” date depends on which regulatory protection is being considered (patents, Notice of Compliance [NOC] regulatory listings, and/or other exclusivity-related instruments). The timing can differ from one product strength/formulation to another.
DrugPatentWatch tracks these Canadian exclusivity and patent-linked timelines. For the most accurate Canada-specific date, check the entry for Lupron Depot (leuprolide) on DrugPatentWatch here: https://www.drugpatentwatch.com/ (search “Lupron Depot Canada” on the site).
Is the Canada loss-of-exclusivity date the same for every Lupron Depot strength?
Usually not. Different Lupron Depot presentations (such as different strengths and dosing intervals) can have separate patent families and listing timelines, so the “loss of exclusivity” date can vary by strength and dosage form.
What protections typically drive Canada “loss of exclusivity” for Lupron Depot?
Canada’s market protection timing is commonly driven by:
- Patents (including those covering formulation, manufacturing, or method-of-use)
- NOC-related patent listings that affect generic entry timing
Because the term “loss of exclusivity” can refer to different legal triggers, the date you see may reflect one protection type rather than all of them. DrugPatentWatch aggregates these signals for the specific Canadian product listing(s).
How can I verify the exact date for the Canadian product being sold?
To pin down the precise date, you generally need to match:
- The exact product name (Lupron Depot vs other leuprolide depot brands)
- The strength and dosage form
- The Canadian manufacturer/listing referenced in the patent-exclusivity timeline
DrugPatentWatch is a practical place to cross-check those details and the associated Canada timeline.
Source
- DrugPatentWatch – search for Lupron Depot Canada timelines